Lessons from TGN1412 and TARGET: Implications for observational studies and meta-analysis

Pharmaceutical Statistics

Volumn 7, Issue 4, 2008, Pages 294-301

  Senn, Stephen ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Bias; Concurrent control; Mean square error; Variance; Veiled trial

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; LUMIRACOXIB; NAPROXEN; PLACEBO; TGN 1412;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OSTEOARTHRITIS; SAMPLE SIZE; SYSTEMATIC ERROR;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; OSTEOARTHRITIS;

EID: 57849097110     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.322     Document Type: Article

References (19)

1. Working Party on Statistical Issues in First-in-Man Studies. Statistical issues in first-in-man studies. Journal of the Royal Statistical Society; Series A 2007; 170(3):517-579.
2. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. The Lancet 2004; 364(9435):665-674.
3. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. The Lancet 2004; 364(9435):675-684.
4. Senn SJ. A personal view of some controversies in allocating treatment to patients in clinical trials [see comments]. Statistics in Medicine 1995; 14(24): 2661-2674.
5. Senn SJ. Covariate imbalance and random allocation in clinical trials [see comments]. Statistics in Medicine 1989; 8(4):467-475.
6. Senn SJ. Testing for baseline balance in clinical trials. Statistics in Medicine 1994; 13(17): 1715-1726.
7. Senn SJ. Added values: controversies concerning randomization and additivity in clinical trials. Statistics in Medicine 2004; 23(24): 3729-3753.
8. Senn SJ. Baseline balance and valid statistical analyses: common misunderstandings. Applied Clinical Trials 2005; 14(3):24-27.
9. Working Party on Statistical Issues in First-in-Man Studies. Report of the Working Party on Statistical Issues in First-in-Man Studies. Royal Statistical Society: London, 2007.
10. Barnard GA. A new test for 2 × 2 tables. Nature 1945; 156:177.
11. Senn SJ. Dicing with death. Cambridge University Press: Cambridge, 2003.
12. Senn SJ. Comment on Farrington and Whitaker: semiparametric analysis of case series data. Journal of the Royal Statistical Society; Series C - Applied Statistics 2006; 55:581-583.
13. Farrington CP, Whitaker HJ. Semiparametric analysis of case series data (with discussion). Journal of the Royal Statistical Society; Series C - Applied Statistics 2006; 55(5):1-28.
14. Julious S. A personal perspective on the Royal Statistical Society report of the working party on statistical issues in first-in-man studies. Pharmaceutical Statistics 2007; 6(2):75-78.
15. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. Journal of Clinical Epidemiology 1992; 45(3):255-265.
16. Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. Statistics in Medicine 1993; 12(24):2273-2284.
17. Senn SJ. The many modes of meta. Drug Information Journal 2000; 34:535-549.
18. van Houwelingen H, Senn S. Investigating underlying risk as a source of heterogeneity in meta-analysis [letter; comment]. Statistics in Medicine 1999; 18(1):110-115.
19. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in Medicine 2002; 21(4):589-624.